Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment, AP reports.
Lilly said the Food and Drug Administration wants information from at least 100 patients who received a minimum of 12 months of continued treatment on donanemab. The drugmaker gave the update after markets closed Thursday.
The potential treatment aims to clear a plaque from the brain that is a key hallmark of the mind-robbing disease.
© Copyright LaPresse